These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30503938)

  • 1. Antitumoral activity of quinoxaline derivatives: A systematic review.
    Montana M; Mathias F; Terme T; Vanelle P
    Eur J Med Chem; 2019 Feb; 163():136-147. PubMed ID: 30503938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinoxaline derivatives: Recent discoveries and development strategies towards anticancer agents.
    Montero V; Montana M; Carré M; Vanelle P
    Eur J Med Chem; 2024 May; 271():116360. PubMed ID: 38614060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity.
    El Newahie AM; Ismail NS; Abou El Ella DA; Abouzid KA
    Arch Pharm (Weinheim); 2016 May; 349(5):309-26. PubMed ID: 27062086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinoxaline Nucleus: A Promising Scaffold in Anti-cancer Drug Discovery.
    Pinheiro AC; Mendonça Nogueira TC; de Souza MV
    Anticancer Agents Med Chem; 2016; 16(10):1339-52. PubMed ID: 27349448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, Characterization and Biological Evaluation of Some Quinoxaline Derivatives: A Promising and Potent New Class of Antitumor and Antimicrobial Agents.
    Al-Marhabi AR; Abbas HA; Ammar YA
    Molecules; 2015 Nov; 20(11):19805-22. PubMed ID: 26540036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase.
    Abbas HA; Al-Marhabi AR; Eissa SI; Ammar YA
    Bioorg Med Chem; 2015 Oct; 23(20):6560-72. PubMed ID: 26420384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents.
    Ajani OO; Nlebemuo MT; Adekoya JA; Ogunniran KO; Siyanbola TO; Ajanaku CO
    Acta Pharm; 2019 Jun; 69(2):177-196. PubMed ID: 31259731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
    Ali I; Lee J; Go A; Choi G; Lee K
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4606-4613. PubMed ID: 28939121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinoxaline: An insight into the recent pharmacological advances.
    Tariq S; Somakala K; Amir M
    Eur J Med Chem; 2018 Jan; 143():542-557. PubMed ID: 29207337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of the antiproliferative activity of novel isoindolo[2,1-a]quinoxaline and indolo[1,2-a]quinoxaline derivatives.
    Desplat V; Moreau S; Belisle-Fabre S; Thiolat D; Uranga J; Lucas R; de Moor L; Massip S; Jarry C; Mossalayi DM; Sonnet P; Déléris G; Guillon J
    J Enzyme Inhib Med Chem; 2011 Oct; 26(5):657-67. PubMed ID: 21250818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinoxalinone as a Privileged Platform in Drug Development.
    Shi L; Hu W; Wu J; Zhou H; Zhou H; Li X
    Mini Rev Med Chem; 2018 Feb; 18(5):392-413. PubMed ID: 29090665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemistry, biological properties and SAR analysis of quinoxalinones.
    Carta A; Piras S; Loriga G; Paglietti G
    Mini Rev Med Chem; 2006 Nov; 6(11):1179-200. PubMed ID: 17100630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF 2,3-DISUBSTITUTED AND FUSED QUINOXALINES AS POTENTIAL ANTICANCER AND ANTIMICROBIAL AGENTS.
    Abbas HS; Al-Marhabi ARM; Ammar YA
    Acta Pol Pharm; 2017 Mar; 74(2):445-458. PubMed ID: 29624250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinoxaline, its derivatives and applications: A State of the Art review.
    Pereira JA; Pessoa AM; Cordeiro MN; Fernandes R; Prudêncio C; Noronha JP; Vieira M
    Eur J Med Chem; 2015 Jun; 97():664-72. PubMed ID: 25011559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of (E)-2-(2-arylhydrazinyl)quinoxalines, a promising and potent new class of anticancer agents.
    Rodrigues FA; Bomfim Ida S; Cavalcanti BC; Pessoa Cdo Ó; Wardell JL; Wardell SM; Pinheiro AC; Kaiser CR; Nogueira TC; Low JN; Gomes LR; de Souza MV
    Bioorg Med Chem Lett; 2014 Feb; 24(3):934-9. PubMed ID: 24398294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinoxaline studies. XIV. Potential anticancer agents. Some quinoxaline amino acid and dipeptide derivatives related to quinoxaline antibiotics.
    Gerchakov S; Schultz HP
    J Med Chem; 1969 Jan; 12(1):141-4. PubMed ID: 5763011
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent Updates on the Anticancer Activity of Quinoxaline Hybrids (Jan. 2017-Jan. 2022).
    Feng LS; Gao C; Liu FW; Wang XP; Zhang ZL
    Curr Top Med Chem; 2022; 22(17):1426-1441. PubMed ID: 36028933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinoxaline and quinoxaline-1,4-di-N-oxides: An emerging class of antimycobacterials.
    Keri RS; Pandule SS; Budagumpi S; Nagaraja BM
    Arch Pharm (Weinheim); 2018 May; 351(5):e1700325. PubMed ID: 29611626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Synthetic Routes to Prepare Biologically Active Quinoxalines and Their Derivatives: A Synthetic Review for the Last Two Decades.
    Khatoon H; Abdulmalek E
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33670436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinoxaline chemistry. Part 13: 3-Carboxy-2-benzylamino-substituted quinoxalines and N-[4-[(3-carboxyquinoxalin-2-yl) aminomethyl]benzoyl]-L-glutamates: synthesis and evaluation of in vitro anticancer activity.
    Corona P; Vitale G; Loriga M; Paglietti G
    Farmaco; 2000 Feb; 55(2):77-86. PubMed ID: 10782376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.